Intrathecal magnetic drug targeting using gold-coated magnetite nanoparticles in a human spine model

Nanomedicine

Volumn 9, Issue 8, 2014, Pages 1155-1169

  Lueshen, Eric ^a   Venugopal, Indu ^a   Kanikunnel, Joseph ^a   Soni, Tejen ^a   Alaraj, Ali ^b   Linninger, Andreas ^a  

^a University of Illinois at Chicago   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

gold coated magnetite nanoparticles; implant assisted magnetic drug targeting; intrathecal drug delivery; intrathecal magnetic drug targeting; magnetic nanoparticles; personalized therapy

Indexed keywords

GOLD COATED MAGNETITE NANOPARTICLE; MAGNETIC NANOPARTICLE; MAGNETITE NANOPARTICLE; NANOPARTICLE; SUPERPARAMAGNETIC NANOPARTICLE; UNCLASSIFIED DRUG; DRUG; GOLD;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EPIDERMIS; HUMAN; HUMAN TISSUE; MAGNET; MAGNETIC FIELD; PRIORITY JOURNAL; SIMULATION; SPINE; SYNTHESIS; VERTEBRAL CANAL; CHEMISTRY; DRUG DELIVERY SYSTEM; MAGNETISM; METABOLISM; PROCEDURES;

DRUG DELIVERY SYSTEMS; GOLD; HUMANS; MAGNETIC PHENOMENA; MAGNETICS; MAGNETITE NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SPINE;

EID: 84906271037     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.69     Document Type: Article

References (65)

1. Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fuid chemotherapy administration and effcacy of therapy in neoplastic meningitis. Cancer 116 (8), 1947-1952 (2010).
2. Stemmler H-J, Mengele K, Schmitt M et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 19(8), 832-836 (2008).
3. Band PR, Holland JF, Bernard J, Weil M, Walker M, Rall D. Treatment of central nervous system leukemia with intrathecal cytosine arabinoside. Cancer 32 (4), 744-748 (1973).
4. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J. Neurosurg. 77(2), 236-240 (1992).
5. Paice JA, Winkelmuller W, Burchiel K, Racz GB, Prager JP. Clinical realities and economic considerations: effcacy of intrathecal pain therapy. J. Pain Symptom Manage. 14(3 Suppl.), S14-S26 (1997).
6. Shahriari A, Khooshideh M. Intrathecal fentanyl added to lidocaine for cesarean delivery under spinal anesthesia-a randomised clinical trial. Middle East J. Anesthesiol. 19 (2), 397-406 (2007).
7. Bani-Hashem N, Hassan-Nasab B, Pour EA, Maleh PA, Nabavi A, Jabbari A. Addition of intrathecal dexamethasone to bupivacaine for spinal anesthesia in orthopedic surgery. Saudi J. Anaesth. 5(4), 382-386 (2011).
8. Luo MC, Zhang DQ, Ma SW et al. An effcient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol. Pain 1, 29 (2005).
9. Hettiarachchi HD, Hsu Y, Harris TJ Jr, Penn R, Linninger AA. The effect of pulsatile fow on intrathecal drug delivery in the spinal canal. Ann. Biomed. Eng. 39(10), 2592-2602 (2011).
10. Ghafoor VL, Epshteyn M, Carlson GH, Terhaar DM, Charry O, Phelps PK. Intrathecal drug therapy for long-term pain management. Am. J. Health Syst. Pharm. 64(23), 2447-2461 (2007).
11. Onofrio BM, Yaksh TL. Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J. Neurosurg. 72(2), 200-209 (1990).
12. Penn RD. Intrathecal medication delivery. Neurosurg. Clin. N. Am. 14(3), 381-387 (2003).
13. Chertok B, Moffat BA, David AE et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 29(4), 487-496 (2008).
14. Chertok B, David AE, Yang VC. Polyethyleneimine-modifed iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials 31(24), 6317-6324 (2010).
15. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic feld topography. J. Control Release 155(3), 393-399 (2011).
16. Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H, Odenbach S. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res. 27(4A), 2019-2022 (2007).
17. Alexiou C, Tietze R, Schreiber E et al. Cancer therapy with drug loaded magnetic nanoparticles-magnetic drug targeting. J. Magnetism Magnetic Mater. 323(10), 1404-1407 (2011).
18. Krukemeyer MG, Wagner W, Jakobs M, Krenn V. Tumor regression by means of magnetic drug targeting. Nanomedicine 4(8), 875-882 (2009).
19. Krukemeyer MG, Krenn V, Jakobs M, Wagner W. Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 Tesla extracorporeal magnets-sarcoma treatment in progress. J. Drug Target. 20(2), 185-193 (2012).
20. Banerjee MK, Datta A, Ganguly R. Magnetic drug targeting in partly occluded blood vessels using magnetic microspheres. J. Nanotechnol. Eng. Med. 1(4), 041005 (2010).
21. Nacev A, Komaee A, Sarwar A et al. Towards control of magnetic fuids in patients: directing therapeutic nanoparticles to disease locations. Control Syst. IEEE 32(3), 32-74 (2012).
22. Mandal M, Kundu S, Ghosh SK et al. Magnetite nanoparticles with tunable gold or silver shell. J. Colloid Interface Sci. 286(1), 187-194 (2005).
23. Sperling RA, Parak WJ. Surface modifcation, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos. Transact. A Math. Phys. Eng. Sci. 368(1915), 1333-1383 (2010).
24. Ouellet JA, Arlet V. Surgical anatomy of the pelvis, sacrum, and lumbar spine relevant to spinal surgery. Semin. Spine Surg. 16(2), 91-100 (2004).
25. Loth F, Yardimci MA, Alperin N. Hydrodynamic modeling of cerebrospinal fuid motion within the spinal cavity. J. Biomech. Eng. 123(1), 71-79 (2001).
26. Ros L, Mota J, Guedea A, Bidgood D. Quantitative measurements of the spinal cord and canal by MR imaging and myelography. Eur. Radiol. 8(6), 966-970 (1998).
27. Ishikawa M, Matsumoto M, Fujimura Y, Chiba K, Toyama Y. Changes of cervical spinal cord and cervical spinal canal with age in asymptomatic subjects. Spinal Cord 41(3), 159-163 (2003).
28. Ko HY, Park JH, Shin YB, Baek SY. Gross quantitative measurements of spinal cord segments in human. Spinal Cord 42(1), 35-40 (2004).
29. Chusid J. Correlative Neuroanatomy and Functional Neurology (19th Edition). Lange Medical Publications, CA, USA (1985).
30. Hsu Y, Hettiarachchi HDM, Zhu DC, Linninger AA. The frequency and magnitude of cerebrospinal fuid pulsations infuence intrathecal drug distribution: key factors for interpatient variability. Anesth. Analg. 115(2), 386-394 (2012).
31. Stockman HW. Effect of anatomical fne structure on the fow of cerebrospinal fuid in the spinal subarachnoid space. J. Biomech. Eng. 128(1), 106-114 (2006).
32. Stockman HW. Effect of anatomical fne structure on the dispersion of solutes in the spinal subarachnoid space. J. Biomech. Eng. 129(5), 666-675 (2007).
33. Bhadelia RA, Bogdan AR, Kaplan RF, Wolpert SM. Cerebrospinal fuid pulsation amplitude and its quantitative relationship to cerebral blood fow pulsations: a phase-contrast MR fow imaging study. Neuroradiology 39(4), 258-264 (1997).
34. Freund M, Adwan M, Kooijman H et al. [Measurement of CSF fow in the spinal canal using MRI with an optimized MRI protocol: experimental and clinical studies]. Rofo 173(4), 306-314 (2001).
35. Henry-Feugeas MC, Idy-Peretti I, Blanchet B, Hassine D, Zannoli G, Schouman-Claeys E. Temporal and spatial assessment of normal cerebrospinal fuid dynamics with MR imaging. Magn. Reson. Imaging 11(8), 1107-1118 (1993).
36. Hamer J, Alberti E, Hoyer S, Wiedemann K. Infuence of systemic and cerebral vascular factors on the cerebrospinal fuid pulse waves. J. Neurosurg. 46(1), 36-45 (1977).
37. Zhu DC, Xenos M, Linninger AA, Penn RD. Dynamics of lateral ventricle and cerebrospinal fuid in normal and hydrocephalic brains. J. Magn. Reson. Imaging 24(4), 756-770 (2006).
38. Laitinen L. Origin of arterial pulsation of cerebrospinal fuid. Acta Neurol. Scand. 44(2), 168-176 (1968).
39. Linninger AA, Tsakiris C, Zhu DC et al. Pulsatile cerebrospinal fuid dynamics in the human brain. IEEE Trans. Biomed. Eng. 52(4), 557-565 (2005).
40. Linninger AA, Xenos M, Sweetman B, Ponkshe S, Guo X, Penn R. A mathematical model of blood, cerebrospinal fuid and brain dynamics. J. Math. Biol. 59(6), 729-759 (2009).
41. Linninger AA, Xenos M, Zhu DC, Somayaji MR, Kondapalli S, Penn RD. Cerebrospinal fuid fow in the normal and hydrocephalic human brain. IEEE Trans. Biomed. Eng. 54(2), 291-302 (2007).
42. Sweetman B, Linninger AA. Cerebrospinal fuid fow dynamics in the central nervous system. Ann. Biomed. Eng. 39(1), 484-496 (2011).
43. Polyak B, Fishbein I, Chorny M et al. High feld gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc. Natl Acad. Sci. USA 105(2), 698-703 (2008).
44. Alexiou C, Diehl D, Henninger P et al. A high feld gradient magnet for magnetic drug targeting. Applied Superconductivity IEEE 16 (2), 1527-1530 (2006).
45. Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome-a life-threatening complication of baclofen pump: a case report. BMC Clin. Pharmacol. 4, 6 (2004).
46. Kao LW, Amin Y, Kirk MA, Turner MS. Intrathecal baclofen withdrawal mimicking sepsis. J. Emerg. Med. 24(4), 423-427 (2003).
47. Bardutzky J, Tronnier V, Schwab S, Meinck HM. Intrathecal baclofen for stiff-person syndrome: life-threatening intermittent catheter leakage. Neurology 60(12), 1976-1978 (2003).
48. Shirley KW, Kothare S, Piatt JH Jr, Adirim TA. Intrathecal baclofen overdose and withdrawal. Pediatr. Emerg. Care 22(4), 258-261 (2006).
49. Perry HE, Wright RO, Shannon MW, Woolf AD. Baclofen overdose: drug experimentation in a group of adolescents. Pediatrics 101(6), 1045-1048 (1998).
50. Vanneste J, Augustijn P. Intrathecal baclofen for treatment of spasticity. J. Neurol. Neurosurg. Psychiatry 53(8), 721 (1990).
51. Dawes WJ, Drake JM, Fehlings D. Microfracture of a baclofen pump catheter with intermittent under-and overdose. Pediatr. Neurosurg. 39(3), 144-148 (2003).
52. Tunali Y, Hanimoglu H, Tanriverdi T, Hanci L, Hanci M. Intrathecal baclofen toxicity and deep coma in minutes. J. Spinal Cord Med. 29(3), 237-239 (2006).
53. James FH, Daniel NS, Henry MS. The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol. 49(18), N309 (2004).
54. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 1(3), 325-327 (2005).
55. Sharma D. A biologically friendly single step method for gold nanoparticle formation. Colloids Surf. B Biointerfaces 85(2), 330-337 (2011).
56. Spitzer HL, Norman JR. The biosynthesis and turnover of surfactant lecithin and protein. Arch. Intern. Med. 127(3), 429-435 (1971).
57. Banat IM, Makkar RS, Cameotra SS. Potential commercial applications of microbial surfactants. Appl. Microbiol. Biotechnol. 53(5), 495-508 (2000).
58. Arima K, Kakinuma A, Tamura G. Surfactin, a crystalline peptidelipid surfactant produced by Bacillus subtilis: isolation, characterization and its inhibition of fbrin clot formation. Biochem. Biophys. Res. Commun. 31(3), 488-494 (1968).
59. Lee JH, Huh YM, Jun YW et al. Artifcially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13(1), 95-99 (2007).
60. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11(11), 2319-2331 (2001).
61. Weissleder R, Stark DD, Engelstad BL et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am. J. Roentgenol. 152(1), 167-173 (1989).
62. Lasagna-Reeves C, Gonzalez-Romero D, Barria MA et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem. Biophys. Res. Commun. 393(4), 649-655 (2010).
63. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 21(23), 10644-10654 (2005).
64. Tomkins A. Assessing micronutrient status in the presence of infammation. J. Nutr. 133(5 Suppl. 2), 1649S-1655S (2003).
65. Jun Y-W, Lee J-H, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew. Chem. Int. Ed. Engl. 47(28), 5122-5135 (2008).